Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17652452 | 0.85 | MTNR1A (0.50) | MTNR1AMTNR1BSIGMAR1POLBHDAC11 | |
| SCHEMBL4418509 | 0.76 | GAA (0.61) | GAALMNAALOX12MAPK1POLB | |
| SCHEMBL11389829 | 0.74 | MTNR1A (0.48) | MTNR1AMTNR1BGAALMNAALOX12 | |
| SCHEMBL7554464 | 0.73 | MTNR1A (0.47) | MTNR1AMTNR1BGAALMNAALOX12 | |
| SCHEMBL27883632 | 0.73 | MTNR1A (0.51) | MTNR1AMTNR1BGAALMNAALOX12 | |
| SCHEMBL7554460 | 0.73 | MTNR1A (0.47) | MTNR1AMTNR1BGAALMNAALOX12 | |
| SCHEMBL7557182 | 0.73 | MTNR1A (0.50) | MTNR1AMTNR1BGAALMNAALOX12 | |
| SCHEMBL10759991 | 0.72 | NOTUM (0.39) | MTNR1AMTNR1BPOLB | |
| SCHEMBL7555842 | 0.72 | MTNR1A (0.40) | MTNR1AMTNR1BGAALMNAALOX12 | |
| SCHEMBL7555837 | 0.72 | MTNR1A (0.40) | MTNR1AMTNR1BGAALMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436500-B1 | TWO PART CURABLE COMPOSITIONS | HENKEL AG & CO KGAA (DE) | 2024-08-07 | — | — | EP | disclosed |
| CN-109071786-B | Two part curable composition | 汉高知识产权控股有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-106715559-B | Curing accelerators for anaerobic curable compositions | 汉高知识产权控股有限责任公司 | 2020-02-28 | — | — | CN | disclosed |
| CN-109071786-A | two part curable composition | 汉高知识产权控股有限责任公司 | 2018-12-21 | — | — | CN | disclosed |
| US-9969690-B2 | Cure accelerators for anaerobic curable compositions | Henkel IP & Holding GmbH (DE) | 2018-05-15 | — | — | US | disclosed |
| EP-3201266-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2017-08-09 | — | — | EP | disclosed |
| US-20170174630-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL AG & CO. KGAA (DE) | 2017-06-22 | — | — | US | disclosed |
| CN-106715559-A | Cure accelerators for anaerobic curable compositions | 汉高知识产权控股有限责任公司 | 2017-05-24 | — | — | CN | disclosed |
| WO-2016054124-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174630-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | AHCY, AHCYL1, CAPG | MTNR1A 3638/4885MTNR1B 4354/4885GAA 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.